Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam
Bags Rights To Hypertension Therapy Zilebesiran
The Swiss major is so keen to get access to Alnylam’s RNAi therapeutic targeting angiotensinogen that it is paying $310m upfront having only seen Phase I data. Some analysts are unsure if it is a good idea.
